PARIS & LONDON--(BUSINESS WIRE)--Regulatory News:
Ipsen (Paris:IPN) (Euronext: IPN) and Spirogen Ltd. announced today that final results from a Phase I clinical trial of the DNA sequence recognizing minor groove binder SJG-136 sponsored by the US National Cancer Institute (NCI) under a Cooperative Research and Development Agreement (CRADA) with Ipsen were presented today at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago by Dr. Igor Puzanov from Vanderbilt-Ingram Cancer Center (Nashville, USA).
